PRESS RELEASE published on 07/12/2025 at 00:00, 6 months 24 days ago BioNxt Solutions Announces Convertible Debenture Unit Private Placement BioNxt Solutions Inc. announces $1.2M non-brokered private placement of convertible debenture units for product development and commercialization Private Placement Convertible Debentures BioNxt Solutions Inc. Commercialization Product Development
BRIEF published on 07/09/2025 at 03:32, 6 months 27 days ago BioNxt Solutions innove dans l'administration ciblée de médicaments de chimiothérapie Oncologie De Précision Solutions BioNxt Administration De Médicaments Innovations Pharmaceutiques Chimiothérapie Ciblée
BRIEF published on 07/09/2025 at 03:32, 6 months 27 days ago BioNxt Solutions Innovates Targeted Chemotherapy Drug Delivery Precision Oncology Drug Delivery BioNxt Solutions Pharmaceutical Innovations Targeted Chemotherapy
PRESS RELEASE published on 07/09/2025 at 03:27, 6 months 27 days ago BioNxt Solutions Introduces Targeted Chemotherapy Drug Delivery Platform for Precision Oncology BioNxt Solutions Inc. announces breakthrough targeted chemotherapy delivery platform for precision oncology, focusing on tumor-specific drug release and neutralization mechanism Precision Oncology BioNxt Solutions Inc. Drug Delivery Targeted Chemotherapy Chemotherapy Market
BRIEF published on 07/07/2025 at 09:10, 6 months 28 days ago BioNxt Advances Sublingual Cladribine Program for MS Pharmaceutical Development Multiple Sclerosis Treatment BioNxt Solutions Sublingual Cladribine Patient Compliance
BRIEF published on 07/07/2025 at 09:10, 6 months 28 days ago BioNxt fait progresser le programme de cladribine sublinguale pour la sclérose en plaques Développement Pharmaceutique Solutions BioNxt Cladribine Sublinguale Conformité Des Patients Traitement De La Sclérose En Plaques
PRESS RELEASE published on 07/07/2025 at 09:05, 6 months 28 days ago BioNxt's Sublingual Cladribine Program for MS Ready for Next Phase BioNxt Solutions receives cladribine API for BNT23001 sublingual thin-film formulation treating multiple sclerosis. Initiates clinical batch production with European partner Gen-Plus GmbH & Co KG Multiple Sclerosis BioNxt Solutions BNT23001 Cladribine API Sublingual Film
BRIEF published on 06/28/2025 at 01:55, 7 months 7 days ago BioNxt Solutions MCTO Revoked by British Columbia Securities Commission Cease Trade Order Annual Filings Trading Resumption Securities Commission BioNxt Solutions
BRIEF published on 06/28/2025 at 01:55, 7 months 7 days ago La Commission des valeurs mobilières de la Colombie-Britannique a révoqué l'autorisation de mise sur le marché de BioNxt Solutions. Dépôts Annuels Commission Des Valeurs Mobilières Solutions BioNxt Reprise Des Échanges Ordonnance De Cessation D'opérations
PRESS RELEASE published on 06/28/2025 at 01:50, 7 months 7 days ago BioNxt Solutions Announces Revocation of Management Cease Trade Order BioNxt Solutions Inc. announces revocation of management cease trade order by British Columbia Securities Commission after filing annual financial statements. Company focuses on bioscience drug technologies Financial Statements Management Cease Trade Order BioNxt Solutions Inc. BioScience Drug Technologies
Published on 02/05/2026 at 01:35, 2 hours 4 minutes ago Dr. Ruben Shiffman Files Early Warning Report in Respect of Greenland Resources
Published on 02/05/2026 at 00:00, 3 hours 39 minutes ago Onco-Innovations Announces Filing of Preliminary Base Shelf Prospectus
Published on 02/04/2026 at 22:25, 5 hours 14 minutes ago 55 North Mining Announces Flow-Through Financing
Published on 02/04/2026 at 16:15, 11 hours 24 minutes ago Trans Canada Gold Enters into an Option Agreement with Bear Mountain Gold Mines to Acquire a 60% Interest in the Harrison Lake District Scale Gold Property, with $10.0 Million Dollars in Prior Exploration Expenditures
Published on 02/04/2026 at 20:54, 6 hours 45 minutes ago Elmos Semiconductor SE is planning to distribute 36 million Euro to shareholders for the fiscal year 2025
Published on 02/04/2026 at 20:36, 7 hours 3 minutes ago EQS-Adhoc: Elmos Semiconductor SE approves share buyback program via the stock exchange of 10 million Euro and dividend proposal of 1.50 Euro per share for fiscal year 2025
Published on 02/04/2026 at 20:00, 7 hours 39 minutes ago Belgium's Ingmar De Vos elected to Executive Board of International Olympic Committee
Published on 02/04/2026 at 18:55, 8 hours 44 minutes ago Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/04/2026 at 18:40, 8 hours 59 minutes ago Robin Zeng: Unlocking the Sustainable Energy Era with Zero-Carbon Technology
Published on 02/04/2026 at 18:04, 9 hours 35 minutes ago Capital et droits de vote au 31 janvier 2026
Published on 02/04/2026 at 18:04, 9 hours 35 minutes ago Total number of voting rights and shares making up the share capital at January 31, 2026
Published on 02/04/2026 at 17:45, 9 hours 54 minutes ago Information concerning the total number of voting rights and shares 2026 01 31
Published on 02/04/2026 at 17:45, 9 hours 54 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
